Myokardia Inc (NASDAQ:MYOK) CFO Taylor C. Harris sold 1,324 shares of Myokardia stock in a transaction dated Friday, April 5th. The shares were sold at an average price of $53.30, for a total value of $70,569.20. Following the completion of the sale, the chief financial officer now owns 3,750 shares of the company’s stock, valued at $199,875. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Shares of MYOK stock opened at $52.39 on Thursday. Myokardia Inc has a fifty-two week low of $39.01 and a fifty-two week high of $67.79. The stock has a market cap of $2.11 billion, a PE ratio of -29.77 and a beta of 2.48.

Myokardia (NASDAQ:MYOK) last issued its quarterly earnings results on Thursday, February 28th. The biotechnology company reported ($0.39) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.46) by $0.07. Myokardia had a negative return on equity of 20.00% and a negative net margin of 201.81%. The business had revenue of $12.40 million for the quarter, compared to analyst estimates of $8.57 million. As a group, research analysts forecast that Myokardia Inc will post -3.16 EPS for the current fiscal year.

Several hedge funds have recently modified their holdings of the company. FMR LLC grew its stake in shares of Myokardia by 0.4% during the fourth quarter. FMR LLC now owns 6,040,606 shares of the biotechnology company’s stock worth $295,144,000 after acquiring an additional 23,296 shares during the last quarter. Vanguard Group Inc grew its stake in shares of Myokardia by 32.8% during the third quarter. Vanguard Group Inc now owns 2,995,821 shares of the biotechnology company’s stock worth $195,328,000 after acquiring an additional 740,607 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Myokardia by 32.8% during the third quarter. Vanguard Group Inc. now owns 2,995,821 shares of the biotechnology company’s stock worth $195,328,000 after acquiring an additional 740,607 shares during the last quarter. BlackRock Inc. grew its stake in shares of Myokardia by 0.3% during the fourth quarter. BlackRock Inc. now owns 2,861,588 shares of the biotechnology company’s stock worth $139,816,000 after acquiring an additional 9,099 shares during the last quarter. Finally, BB Biotech AG grew its stake in shares of Myokardia by 72.0% during the fourth quarter. BB Biotech AG now owns 877,266 shares of the biotechnology company’s stock worth $42,863,000 after acquiring an additional 367,266 shares during the last quarter. Institutional investors and hedge funds own 90.88% of the company’s stock.

Several equities analysts have issued reports on MYOK shares. BidaskClub lowered Myokardia from a “hold” rating to a “sell” rating in a research note on Saturday, February 9th. TheStreet upgraded Myokardia from a “d+” rating to a “c-” rating in a research note on Thursday, April 4th. Zacks Investment Research lowered Myokardia from a “hold” rating to a “sell” rating in a research note on Tuesday, March 5th. ValuEngine upgraded Myokardia from a “buy” rating to a “strong-buy” rating in a research note on Friday, April 5th. Finally, Credit Suisse Group cut their target price on Myokardia from $73.00 to $71.00 and set an “outperform” rating on the stock in a research note on Friday, January 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $75.27.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.watchlistnews.com/taylor-c-harris-sells-1324-shares-of-myokardia-inc-myok-stock/2954808.html.

Myokardia Company Profile

MyoKardia, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which is in Phase III clinical trial that is designed to reduce left ventricular contractility to alleviate the functional consequences and symptoms of obstructive hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression, as well as in Phase II clinical trial for non-obstructive HCM.

See Also: Commodities

Insider Buying and Selling by Quarter for Myokardia (NASDAQ:MYOK)

Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.